Skip to content

Efficacy of Symbicort Versus Its Monocomponents - SPRUCE 160/4.5

A 12 Week, Randomized, Double-blind, Double-dummy, Placebo-controlled Trial of Symbicort TM (160/4.5mcg) Versus Its Mono-products (Budesonide and Formoterol) in Adolescents (at Least 12 Years of Age) and Adults With Asthma - SPRUCE 160/4.5

Status
Completed
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00652002
Enrollment
450
Registered
2008-04-03
Start date
2002-07-31
Completion date
2004-01-31
Last updated
2011-01-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Asthma

Keywords

Asthma, Symbicort, budesonide/formoterol, budesonide, formoterol

Brief summary

The purpose of this study is to compare Symbicort with budesonide alone and with formoterol alone in the treatment of asthma in adolescents and adults

Interventions

DRUGbudesonide/formoterol
DRUGbudesonide
DRUGformoterol

Sponsors

AstraZeneca
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Caregiver, Investigator)

Eligibility

Sex/Gender
ALL
Age
12 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* At least 12 years of age * Diagnosis of asthma * Baseline lung function test results as determined by protocol and required and received treatment with inhaled corticosteroids and/or lung treatments specified in protocol within the timeframe and doses specified in the protocol

Exclusion criteria

* Has required treatment with non-inhaled corticosteroids within previous 4 weeks, has sensitivity to drugs specified in the protocol or requires treatment with beta-blockers * Had cancer within previous 5 years or currently has any other significant disease or disorder as judged by the investigator

Design outcomes

Primary

MeasureTime frame
12 hour serial FEV1 measurements and withdrawals due to asthma exacerbationFEV1: before start of tretment and at 2 and 12 weeks after start of treatment. Withdrawals: throughout the treatment period

Secondary

MeasureTime frame
Lung function, asthma symptoms, use of rescue medication, adverse events and other safety assessmentsThroughout the treatment period

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 27, 2026